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Abstract: BACKGROUND Clearly structured and comprehensive protocols are an essential component
to ensure safety of participants, data validity, successful conduct, and credibility of results of randomized
clinical trials (RCTs). Funding agencies, research ethics committees (RECs), regulatory agencies, medi-
cal journals, systematic reviewers, and other stakeholders rely on protocols to appraise the conduct and
reporting of RCTs. In response to evidence of poor protocol quality, the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) guideline was published in 2013 to improve the accuracy
and completeness of clinical trial protocols. The impact of these recommendations on protocol com-
pleteness and associations between protocol completeness and successful RCT conduct and publication
remain uncertain. OBJECTIVES AND METHODS Aims of the Adherence to SPIrit REcommendations
(ASPIRE) study are to investigate adherence to SPIRIT checklist items of RCT protocols approved by
RECs in the UK, Switzerland, Germany, and Canada before (2012) and after (2016) the publication of
the SPIRIT guidelines; determine protocol features associated with non-adherence to SPIRIT checklist
items; and assess potential differences in adherence across countries. We assembled an international
cohort of RCTs based on 450 protocols approved in 2012 and 402 protocols approved in 2016 by RECs in
Switzerland, the UK, Germany, and Canada. We will extract data on RCT characteristics and adherence
to SPIRIT for all included protocols. We will use multivariable regression models to investigate temporal
changes in SPIRIT adherence, differences across countries, and associations between SPIRIT adherence of
protocols with RCT registration, completion, and publication of results. We plan substudies to examine
the registration, premature discontinuation, and non-publication of RCTs; the use of patient-reported
outcomes in RCT protocols; SPIRIT adherence of RCT protocols with non-regulated interventions; the
planning of RCT subgroup analyses; and the use of routinely collected data for RCTs. DISCUSSION The
ASPIRE study and associated substudies will provide important information on the impact of measures
to improve the reporting of RCT protocols and on multiple aspects of RCT design, trial registration,
premature discontinuation, and non-publication of RCTs observing potential changes over time.
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Abstract
Background: Clearly structured and comprehensive protocols are an essential component to ensure safety of
participants, data validity, successful conduct, and credibility of results of randomized clinical trials (RCTs). Funding
agencies, research ethics committees (RECs), regulatory agencies, medical journals, systematic reviewers, and other
stakeholders rely on protocols to appraise the conduct and reporting of RCTs. In response to evidence of poor
protocol quality, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline was
published in 2013 to improve the accuracy and completeness of clinical trial protocols. The impact of these
recommendations on protocol completeness and associations between protocol completeness and successful RCT
conduct and publication remain uncertain.
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Objectives and methods: Aims of the Adherence to SPIrit REcommendations (ASPIRE) study are to investigate
adherence to SPIRIT checklist items of RCT protocols approved by RECs in the UK, Switzerland, Germany, and
Canada before (2012) and after (2016) the publication of the SPIRIT guidelines; determine protocol features
associated with non-adherence to SPIRIT checklist items; and assess potential differences in adherence across
countries.
We assembled an international cohort of RCTs based on 450 protocols approved in 2012 and 402 protocols
approved in 2016 by RECs in Switzerland, the UK, Germany, and Canada. We will extract data on RCT characteristics
and adherence to SPIRIT for all included protocols. We will use multivariable regression models to investigate
temporal changes in SPIRIT adherence, differences across countries, and associations between SPIRIT adherence of
protocols with RCT registration, completion, and publication of results.
We plan substudies to examine the registration, premature discontinuation, and non-publication of RCTs; the use of
patient-reported outcomes in RCT protocols; SPIRIT adherence of RCT protocols with non-regulated interventions;
the planning of RCT subgroup analyses; and the use of routinely collected data for RCTs.
Discussion: The ASPIRE study and associated substudies will provide important information on the impact of
measures to improve the reporting of RCT protocols and on multiple aspects of RCT design, trial registration,
premature discontinuation, and non-publication of RCTs observing potential changes over time.
Keywords: Randomized clinical trials, Trial protocol, Reporting quality, Reporting guideline adherence, Registration,
Trial discontinuation
Introduction
Protocols are essential documents for the planning, con-
duct, and reporting of randomized clinical trials (RCTs)
[1]. Empirical studies investigating cohorts of clinical
trial protocols from the 1990s found the reporting qual-
ity of RCT protocols to be limited, specifically in the
description of treatment allocation methods, primary
outcomes, use of blinding, adverse events reporting,
sample size calculations, data analysis, and the roles of
sponsors in trial design or access to data [2–9].
Ethical and practical implications of deficient trial
protocols
Inadequately reported or incomplete RCT protocols may
have serious implications for sponsors, trial staff, in-
volved patients, systematic reviewers, and other users of
trial results. A lack of key elements in a protocol may
lead to missing or unreliable data compromising the val-
idity of trial results; low quality trial protocols may be
associated with insufficient planning and unsuccessful
conduct of a trial, premature trial discontinuation, and
eventual non-publication [10]—potentially putting
participants at unnecessary risk with minimal scientific
return on the investment [11, 12]. In addition, partici-
pants may suffer due to ill-informed treatment decisions
based on compromised trial evidence. If important
details are missing from the protocol, peer reviewers,
journal editors, clinicians, or systematic reviewers may
not be able to identify discrepancies between the pub-
lished report of a clinical trial and the protocol [4],
which can be relevant, for instance, when judging the
credibility of subgroup effects or identifying measured
but not reported outcomes [4, 13, 14].
SPIRIT—reporting guideline for trial protocols
In 2007, the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) Initiative began work-
ing to improve the completeness of clinical trial proto-
cols and, in January 2013, published evidence-based
recommendations for a minimum set of items to be ad-
dressed in trial protocols [12, 15]. According to the Web
of Science, the SPIRIT publications have been cited al-
most 3000 times, as of September 25, 2020. An import-
ant aspect of the implementation of the SPIRIT
guideline is to evaluate its impact on the reporting qual-
ity of trial protocols over time. So far, there are only a
few studies that have used [16] or plan to use [17] the
SPIRIT checklist as a tool to assess the completeness of
trial protocols. Kyte et al. investigated patient-reported
outcomes in 75 RCT protocols supported by the UK Na-
tional Institute for Health Research (NIHR) Health
Technology Assessment (HTA) programme from 2012
and 2013 and examined whether the quality of reporting
of patient-reported outcomes was associated with overall
protocol completeness [16]. They found that protocols
adhered on average to 63% of 51 SPIRIT recommenda-
tions giving items and subitems of the checklist equal
weights. Madden et al. focused in a planned study on
the reporting of the statistics section in published surgi-
cal trial protocols using 11 items from the SPIRIT
checklist [17]. Thabane et al. plan to assess the reporting
quality of cluster randomized trials with a stepped wedge
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design, including protocols of such trials using the SPIR
IT checklist, but they do not provide details about which
SPIRIT items or subitems will be assessed and how these
will be weighted in their analysis [18].
Rationale for meta-epidemiological research with RCT
protocols
Clearly structured and comprehensive study protocols
are essential to ensure the safety and well-being of study
participants, data validity, and credibility of results, par-
ticularly in the case of RCTs. Incomplete protocols
jeopardize all stages of the clinical research process with
potentially harmful consequences for patients, decision-
making in health care, the scientific community, and so-
ciety as a whole. Since most evidence on the accuracy
and completeness of trial protocols dates back to the
1990s, empirical evidence from more recent protocols is
needed. In particular, the potential effect of the publica-
tion of the SPIRIT recommendations on the quality of
RCT protocols remains unclear.
The Adherence to SPIrit REcommendations (ASPIRE)
study group is an international collaboration of re-
searchers which aims to evaluate the completeness of
RCT protocols approved by RECs in the UK (Bristol
regional office), Switzerland (Basel, Bern, Geneva,
Lausanne, St. Gallen, Thurgau [from 2016 together with
St. Gallen], Bellinzona, and Zurich), Germany (Freiburg),
and Canada (Hamilton) before publication of the SPIRIT
statement (in 2012) and thereafter (in 2016).
In addition to recently published work on phase I trials
and multi-arm trials [19, 20], the secondary objectives of
the ASPIRE study include examining trial registration,
premature discontinuation, and non-publication of
RCTs; the use of patient-reported outcomes and specif-
ically of health-related quality of life (HRQoL) outcomes
in RCT protocols; the protocol quality of RCTs with reg-
ulated vs non-regulated interventions; the planning of
subgroup analyses in RCT protocols; and the planned
use of routinely collected data in RCTs.
Study objectives
Our focus is on RCTs because their results typically im-
pact clinical practice and guidelines. Furthermore, par-
ticipants in RCTs are exposed to risks and burdens that
invoke a fiduciary responsibility on the part of clinical
trial investigators to ensure that the trial is conducted to
the highest methodological standard.
Specific objectives of the ASPIRE study are as follows:
1. To compare the completeness of RCT protocols
approved by RECs in the UK, Switzerland,
Germany, and Canada before (2012) the publication
of the SPIRIT checklist (January 2013) and
thereafter (2016) based on the protocol adherence
to SPIRIT checklist items.
2. To determine trial characteristics associated with
non-adherence to SPIRIT checklist items including
potential interactions between year of approval
(2012 or 2016) and sponsorship of protocols, and
year of approval (2012 or 2016) and reported
methodological support from Clinical Trial Units or
Clinical Research Organisations.
3. To investigate whether the comprehensiveness of
RCT protocols is different across countries
(Switzerland, Germany, Canada, the UK).
Additional objectives and rationales for substudies of
ASPIRE
1. Subproject 1, DISCOntinued trials (DISCO) II: Our
previous study of RCT protocols approved by Swiss,
Canadian, or German RECs between 2000 and 2003
found that one out of four initiated RCTs was
prematurely discontinued and that only 70% of
completed and less than 50% of discontinued RCTs
were published in peer-reviewed journals [10]. This
is especially worrying, as results from published
trials are systematically different from unpublished
trials [21–23]. Public trial registries are meant to
provide a comprehensive overview of all ongoing
clinical trials, which can help reduce duplication in
research and minimize publication bias [24].
However, even though the International Committee
of Medical Journal Editors (ICMJE) mandated
prospective registration of trials which started
enrolment after July 2005 as a requirement for
publication, it is still common for RCTs to be
registered after completion or not at all [25, 26].
Furthermore, there are often discrepancies between
data in trial registries and the corresponding
publication of an RCT with respect to important
items, such as the primary outcome [26].
We will use RCTs included in the ASPIRE study (the
UK, Switzerland, Germany, and Canada) to evaluate: (i)
the extent of registered and, in particular, prospectively
registered protocols in national or international regis-
tries; (ii) the proportion of prematurely discontinued
RCTs and reasons for discontinuation; (iii) the propor-
tion of RCTs not published in a peer-reviewed journal
or without results posted in a public trial registry; (iv)
the extent to which unpublished RCTs (in particular
those that were prematurely discontinued) can be identi-
fied through trial registries; (v) whether the proportions
of trials under categories (i)–(iv) vary across RECs in dif-
ferent countries; and (vi) whether the completeness of
reporting of RCT protocols according to SPIRIT is
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associated with the proportion of discontinued RCTs
due to poor recruitment or non-publication of RCT re-
sults (i.e. neither in a peer-reviewed journal, nor in a
trial registry). We propose to compare the RCT cohorts
from 2012 and 2016 with RCTs approved 2000–2003
from the previous DISCO study [10, 27]. We will also
investigate the agreement of trial characteristics between
the approved study protocols (later amendments consid-
ered), registry data, and journal publications (e.g.
primary outcome, patient eligibility criteria).
2. Subproject 2, Patient-reported outcomes: Patient-
reported outcomes and specifically the subgroup of
HRQoL outcomes are highly relevant for decision
making in health care and policy [28–30]. Nonethe-
less, patient-reported outcomes, including HRQoL,
are infrequently considered in RCTs [31], or
specified in protocols but not reported in RCT
publications [31–34].
We plan to investigate the prevalence and
characteristics of patient-reported outcomes in RCT
protocols approved in 2012 and 2016 and their
reporting in corresponding publications. In particu-
lar, we will compare the prevalence of HRQoL
outcomes in protocol cohorts of 2012 and 2016
with RCT protocols approved in 2000–2003 [34].
3. Subproject 3, Non-regulated interventions: Trials
with “regulated interventions” such as drugs,
biologics, or medical devices are controlled by
regulatory agencies; trials with “non-regulated
interventions” such as dietary interventions, surgical
procedures, behavioural and lifestyle interventions,
or exercise programmes are not reviewed by
regulatory agencies. RCTs evaluating regulated
interventions may, therefore, be associated with
higher quality protocols, greater likelihood of
registration, lower risk for selective outcome
reporting bias, and a higher likelihood of
publication [35–39].
We will determine the prevalence of RCTs
evaluating non-regulated interventions and
investigate whether their associated protocols are
associated with lower adherence to SPIRIT
recommendations in comparison with RCT
protocols testing regulated interventions. In
addition, we will identify individual SPIRIT checklist
items with lowest adherence in RCT protocols
testing non-regulated interventions.
4. Subproject 4, Subgroups: In a previous study with
RCT protocols approved between 2000 and 2003,
we found that almost 30% of protocols included
one or more planned subgroup analyses [13];
however, most were poorly reported: Only 7%
provided a clear hypothesis for at least one
subgroup analysis, 4% anticipated the direction of a
subgroup effect, and 35% planned a statistical test
for interaction. Industry-sponsored trials more often
planned subgroup analyses compared with
investigator-sponsored trials (35% versus 17%).
We will investigate if the prevalence and
description of subgroup analyses in RCT protocols
from 2012 and 2016, stratified by medical discipline,
differ from those approved in the early 2000s [13].
In addition, we will assess the percentage of
planned subgroup analyses based on molecular
markers in RCT protocols from 2012 and 2016.
5. Subproject 5, Routinely collected data: Using
routinely collected data may facilitate the planning
and conduct of RCTs [40]. For instance, data from
electronic health records (EHRs), registries, or
administrative claims data can be used to efficiently
collect outcome data for RCTs, or targeted
screening of routine data may enhance the
recruitment of eligible patients. It is unclear how
often and for which purposes routinely collected
data are actually used in RCTs.
We will investigate the prevalence, characteristics,
and purposes of routinely collected data for RCTs
described in protocols from 2012 and 2016,
stratified by medical discipline.
Methods
This meta-research study will be conducted by the
Adherence to SPIrit REcommendations (ASPIRE) study
group, an international collaborative group of
researchers involving all RECs in Switzerland (Basel,
Bellinzona, Bern, Geneva, Lausanne, St. Gallen, Thurgau
(from 2016 together with St. Gallen), Zurich), as well as
one REC in Germany (Freiburg), one REC in Canada
(Hamilton), and the Bristol office of the UK National Re-
search Ethics Service (which is responsible for 19 RECs
in the UK). We have obtained support and established
cooperation with the aforementioned RECs, building on
successfully completed prior research [10].
While the main ASPIRE study examining SPIRIT
checklist items was conceived as a joint analysis among
all involved RECs, there were differences in the timeline
to access protocols from 2016 in different countries. As
such, the main ASPIRE study will be conducted separ-
ately for the UK RECs.
Eligibility criteria for study sample
We will include protocols of all approved RCTs in 2012
and 2016 that compared an intervention with placebo, a
sham intervention, another active intervention, or no
intervention or combinations thereof. We define an RCT
as a prospective study in which patients, or groups of
patients, are assigned at random to one or more
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interventions to evaluate their effect on health outcomes.
Studies comparing different doses or routes of adminis-
tration of the same drug and trials labelled as pilot or
feasibility studies will be included but represent two pre-
specified subgroups. We will exclude studies enrolling
healthy volunteers (e.g. pharmacokinetic studies, training
interventions in sport science), economic evaluations,
animal studies, studies based on tissue samples, observa-
tional studies, studies involving only qualitative methods,
and studies with a quasi-random method of allocation.
RCT selection process
We have already screened in detail all studies approved
by RECs in Switzerland, in Freiburg (Germany), and in
Hamilton (Canada) in 2012 and 2016 using the above-
described criteria. For feasibility reasons, we have ac-
quired a stratified (by tertile of submission) random
sample of 45 studies per year from protocols approved
in Freiburg and Hamilton. In addition, we drew a strati-
fied random sample of 60 protocols out of all 148 eli-
gible RCT protocols approved by the REC in Zurich in
2012. Figure 1a and b illustrate the RCT selection
process for RECs in Switzerland, Germany, and Canada.
Detailed flow diagrams illustrating the selection process
for protocols from RECs in the UK will be provided at a
later stage.
Confidentiality when handling RCT protocols
The involved Swiss, German, UK, and Canadian RECs
are all project partners, and we are collaborating with a
mandate from each participating REC [10]. All re-
searchers extracting data from RCT protocols signed
confidentiality agreements to conduct the outlined pro-
jects according to quality assurance measures and to
confidentially handle the information contained in REC
files. Only aggregated data will be published, and none
of the primary studies, investigators, or sponsors will be
identifiable. The final database will only contain data
with coded trial identification numbers.
Data collection for the ASPIRE study
We will use a web-based, password-protected data ex-
traction tool (http://www.squiekero.org) for data collec-
tion and data storage [10]. The data extraction sheets in
the form of electronic database entry forms were devel-
oped and piloted by our team with protocols from the
REC in Basel. We compiled a manual with definitions
and rules for data extraction for each variable. We will
extract the following data for the ASPIRE study:
1. Information on centre and protocol (e.g. sponsor,
funding source(s))
2. Trial characteristics (e.g. medical field, type of
patient, intervention, number of centres, number of
study arms, planned sample size)
3. Specific individual SPIRIT checklist items [12]
(whether they are reported in the protocol: “Yes”,
“No”, or “Not applicable”)
The complete SPIRIT checklist includes 270 individual
components grouped under 33 separate headings. For
instance, the heading “sample size calculation” has nine
components which are relevant to the calculation of
sample size, including but not limited to the statistical
test used to calculate the sample size, type I error, type
II error, and the minimum anticipated difference or
event rate. For our assessment, we will consider all 33
major items or subitems indicated by letters (e.g. 18a,
18b) of the SPIRIT checklist. However, we need to
operationalize the checklist for data extraction purposes,
i.e. some of the individual components of SPIRIT items
or subitems will not be considered, because we feel that
such a level of detail is not helpful for our empirical ana-
lysis and adds unnecessary complexity and burden for
data extractors. The process of identifying which compo-
nents to include in data extractions was as follows. First,
all items and components were included where the
heading related to the formulation of a research question
using the PICO structure (Population, Intervention,
Comparator and Outcome). These were headings that
defined the target population, defined the intervention
used and any comparators, and defined the outcomes of
the study. These headings were considered important
because they are relevant to defining the research ques-
tion of interest for each clinical trial. Likewise, all SPIR
IT items were included for headings related to sample
size calculation, random sequence generation, allocation
concealment, and blinding. These headings were chosen
because of their importance for reducing bias in clinical
trials.
For the remaining SPIRIT headings, two investigators
(AO and BN) independently reviewed each of the items
and components under the heading and selected compo-
nents that encompassed the core message of the head-
ing. These selections were compared and reviewed with
three additional collaborators (SH, MB, and Prof.
Douglas G. Altman) to achieve consensus on the final
selection. A copy of the data extraction forms is pro-
vided in Additional file 1, and a list of the 64 items and
components selected from the SPIRIT checklist for as-
sessment is provided in Additional file 2.
We will extract data from included RCT protocols in
teams of two researchers with methodological training
working independently with subsequent agreement
checks and consensus discussions in case of discrepan-
cies. Each reviewer will be trained and successfully
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complete calibration exercises before starting data ex-
traction. Our aim is to extract more than 80% of all in-
cluded RCT protocols independently and in duplicate;
single extractions will only be performed by experienced
data extractors (having extracted at least 100 RCT pro-
tocols in duplicate before doing single extractions) to
minimize extraction errors.
Data collection for Subproject 1 (DISCO II study)
We will review all eligible RCT protocols and other
available REC files for details regarding registration
numbers for any primary trial registry. We will search
the WHO International Clinical Trials Registry Platform
(www.who.int/ictrp), clinicaltrials.gov, and the European
Clinical Trials Database (EudraCT) for a corresponding
registered RCT, and for those without an obvious regis-
tration number, we will consider the population, inter-
vention, control, or primary outcome of a respective
RCT as search terms in combination with the name of
the principal investigator. For RCTs where we are unable
to identify a corresponding record in any of these regis-
tries, we will use the Google Web search engine. If a
registration number cannot be found, we will categorize
RCT protocols as “not registered”. Of the registered pro-
tocols, we will extract the date of first registration and
the date of entry of the first RCT participant, sponsor,
funding source(s), planned sample size, recruitment
milestones, primary outcome(s), date of last update,
A B
Fig. 1 a Flow diagram for included randomized clinical trial protocols in ASPIRE with ethics approval in 2012. b Flow diagram for included
randomized clinical trial protocols in ASPIRE with ethics approval in 2016
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status of the trial, and if results are available in each
registry. We define “prospectively registered protocols”
as protocols with a date of first registration within a
month of the entry date of the first RCT participant to
allow for processing delays in the registry and to ensure
comparability with previous studies examining trial
registration (e.g. [41, 42]).
We will evaluate how many approved RCT protocols
result in a peer reviewed full-text publication, how many
provide results in a trial registry, and how many have
both, peer-reviewed publications and results published
in a trial registry. Full texts will be identified directly
from trial registries or through individual searches of
PubMed and Scopus (one of the most comprehensive
databases [43]), in addition to Google Scholar and the
Google Web search engine if necessary [44]. We will
contact the principal investigator of an RCT to inquire
whether there is a corresponding publication in the fol-
lowing cases: (i) no registry entry and no publication can
be identified or (ii) the RCT is registered and the study
completion date was more than 2 years prior and no
full-text publication was identified and results are not
published in the trial registry. In case that the study is
registered and the status is “ongoing”, we will contact
the principal investigator to ask if the status of the clin-
ical trial registry is correct or if the RCT was completed
or discontinued. We will extract in duplicate the same
information items from full-text publications as from
trial registries (see above).
We plan to contact investigators of RCTs, which (i)
were neither registered nor published, (ii) were regis-
tered and labelled as “ongoing” but the status has not
been updated within the last 2 years, or (iii) for which
any of the following outcomes remains unclear: pro-
spective registration, premature discontinuation, reason
for discontinuation, or non-publication.
Data collection for Subproject 2 (Patient-reported
outcomes study)
In RCT protocols with specified patient-reported out-
comes, we will extract (i) whether they specifically con-
sider HRQoL outcomes, (ii) all specified individual
patient-reported outcomes, (iii) whether any patient-
reported outcome is specified as a primary outcome, (iv)
the type of instrument used, (v) whether there is any
evidence of validation of the instrument provided, (vi)
whether there is an explicit hypothesis specified, (vii) the
method of data collection for each patient-reported
outcome, (viii) whether a patient-reported outcome is
considered in the power/sample size calculation, and (ix)
whether a validated minimal important difference is
reported. We based our data extraction form for patient-
reported outcomes on the CONSORT PRO (Consolidated
Standards of Reporting Trials with patient-reported
outcomes) tool [45], developed to improve the reporting
of patient-reported outcomes in RCTs, as well as the Food
and Drug Administration’s “Guidance for Industry” on the
use of patient-reported outcomes in medical product de-
velopment [30].
We will categorize patient-reported outcomes as
assessing patients’ well-being measured by (i) a disease-
specific HRQoL measure (e.g. Asthma QoL question-
naire); (ii) a multi- or uni-dimensional generic HRQoL
instrument (e.g. Short Form-36); (iii) an overall sense of
well-being in one question (holistic HRQoL), (iv)
patient-reported physical functioning; (v) patient-
reported mental/emotional functioning; (vi) patient-
reported social functioning; and (vii) reporting of
symptoms (e.g. pain). The definition of HRQoL includes
only the first three categories (i–iii).
Data collection for Subproject 3 (Non-regulated
interventions study)
No additional data collection is necessary for this
substudy.
Data collection for Subproject 4 (Subgroups study)
In addition to the data extraction for ASPIRE, we will
extract information on whether any subgroup analysis is
mentioned in the protocol and, if so, whether the ana-
lysis is deemed exploratory or confirmatory, whether a
clear hypothesis for a subgroup effect is prespecified,
whether a direction for this effect is indicated, and
whether interaction testing for this part is predeter-
mined. Also, we will record information on the subgroup
variables and outcomes for the subgroup analysis, num-
ber of subgroup analyses planned, and whether the sub-
group analyses are considered in the sample size
calculation (if explicitly planned as confirmatory
analysis).
Data collection for Subproject 5 (Routinely collected data
study)
We will extract whether routinely collected data were
used in any way to support the planning or conduct of
all included RCTs, and document the specific type of
routinely collected data (e.g. electronic health records,
claims data) and their purpose (e.g. outcome data collec-
tion) in respective RCTs.
Operationalization of the SPIRIT checklist and statistical
analysis of ASPIRE
Data cleaning and analysis will be performed using R
version 3.6.1 [46].
The SPIRIT checklist contains 33 different major
items. Taking the multiple components and subitems
(e.g. #5a-d) into account, we prespecified a total of 64
variables to be extracted from each trial protocol to
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measure adherence to SPIRIT. These 64 variables can
take the values “Yes”, “No”, or “Not applicable”. Differ-
ent scenarios in terms of data structure are possible
depending on the complexity of each SPIRIT item:
Single SPIRIT items (type 1 variables) SPIRIT items
only requiring a single variable (n = 19 items and n = 19
variables in total; SPIRIT items number 1–4, 7–9, 13,
19, 22–25, 27–30, 32–33).
Multiple component items (type 2 variables) SPIRIT
items requiring more than one variable (n = 4 SPIRIT
items: 10 (3 variables), 12 (3 variables), 14 (6 variables),
15 (3 variables)).
Multiple explicit subitems (type 3 variables) SPIRIT
items which consist of multiple subitems and for which
we extracted one variable for each subitem (n = 8 SPIR
IT items: 5 (a–d), 6 (a, b), 16 (a–c), 18 (a, b), 20 (a–c),
21 (a, b), 26 (a, b), 31 (a–c)).
Multiple explicit subitems with several components
in subitems (type 4 variables) SPIRIT items which con-
sist of multiple subitems and for which we extracted
more than one variable for one of the subitems (n = 2
SPIRIT items: 11 (a–d) with 2 variables for 11a, and 17
(a, b) with 3 variables for 17a).
We will use three different approaches to calculate ad-
herence to the SPIRIT checklist (Table 1).
In the primary analysis, we will use the following
approach:
1. Major item approach (allowing for partial credit of
individually met subitems or components of major
SPIRIT items): for each type 1 variable, we will
assign one point for each “Yes” or “Not applicable”.
We will assign a fraction of one point for each sub-
variable in type 2 and type 3 variables. For example,
if there are two sub-variables, each will be assigned
0.5 points for a “yes”. In case there are 3 sub-
variables, each will be assigned 1/3 point. For type 4
variables, we will apply the same rule, i.e. for ex-
ample item #17 consists of 17a and 17b. Each of
these will be assigned 0.5 points in case of a “yes” or
“not applicable”; however, #17a consists of three
components, and therefore, each of these type 4
variables will be assigned 1/3 of 0.5 (=0.1667) points
in case of a “Yes” or “Not applicable”. A “No” will
lead to zero points in each case. The maximum pos-
sible score with this approach will be 33 points.
In sensitivity analyses, we will use the following
approaches:
2. Major item approach (simple): For each of the 33
major SPIRIT items, we will assign one point for
each “Yes” or “Not applicable” in type 1 variables,
and one point if all type 2, type 3, and type 4
variables contingent to a major SPIRIT item are
“Yes” or “Not applicable”. Otherwise, zero points
will be assigned. The maximum possible score with
this approach will be 33 points.
3. All item approach: For each “Yes” or “Not
applicable” in each variable (types 1, 2, 3, or 4), we
will assign one point. A “No” will be assigned zero




Item hierarchy Value Assigned points according to approach
Major items (simple) Major items (allowing for partial credit) All items
1 (total) Major item Yes 1 1 1
… … … … … …
17 (total) Major item No 0 0.8334 3
17a.1 Component 1 of subitem 17a No n/a 0.1667 1
17a.2 Component 2 of subitem 17a Yes n/a 0.1667 1
17a.3 Component 3 of subitem 17a No n/a 0 0
17b Subitem 17b Yes n/a 0.5 1
… … … … … …
20 (total) Major item Yes 1 1 3
20a Subitem 20a Yes n/a 0.3333 1
20b Subitem 20b Yes n/a 0.3333 1
20c Subitem 20c Yes n/a 0.3333 1
… … … … … …
n/a not applicable, SPIRIT Standard Protocol Items: Recommendations for Interventional Trials
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points. The maximum possible score with this
approach will be 64 points.
Regarding major item 17 of SPIRIT in Table 1, for in-
stance, component 1 of subitem 17a (blinding status of
participants) is reported, component 2 of subitem 17a
(blinding status of care providers) is reported, component
3 of subitem 17a (blinding status of outcome assessors) is
not reported, and subitem 17b (conditions when unblind-
ing is permissible) is reported. With the “simple Major
item approach”, we assign item 17 a total of 0, because
not all components of subitems were reported; with the
“Major item approach allowing for partial credit”, a total
of 0.8334 is assigned, because only one component of sub-
item 17a was not reported; and with the “all item ap-
proach”, we assign a total of 3 points, because all reported
components or subitems receive a point.
In further sensitivity analyses, we will repeat the calcu-
lations with each of the mentioned approaches but will
assign points only in case of a “Yes” for a specific vari-
able; in case of “Not applicable”, we will assign neither
one nor zero points, but will not consider this item for a
specific protocol. This means that the maximum pos-
sible score could vary across protocols for each of the
three approaches.
Our main outcome will be adherence to SPIRIT
checklist items reported in RCT protocols approved by
RECs in 2012 and in 2016. We will calculate adherence
as the proportion of trial protocols that address each in-
dividual SPIRIT checklist item (according to the differ-
ent approaches described above) as the mean/median
number of items adhered to per protocol. Our main ana-
lyses will be based on the major item approach allowing
for partial credit of individually met subitems or compo-
nents of major SPIRIT items with “not applicable” get-
ting assigned a point because it keeps the hierarchical
structure of the SPIRIT checklist and it independently
considers all components and subitems of all individual
SPIRIT items.
For descriptive analyses, we will stratify included pro-
tocols by the year of approval (2012 versus 2016), spon-
sorship (industry versus investigator), sample size (above
vs below/equal to the median sample size), centre status
(single vs multicentre RCTs), and reported methodo-
logical support (yes vs no). To analyse whether the fol-
lowing independent variables are associated with
adherence to a larger proportion of SPIRIT items
(dependent variable), we will use multivariable regres-
sion models (beta regression [47]—primary analysis, and
hierarchical logistic regression):
1. Year 2012 versus 2016 (Hypothesis: RCT protocols
approved in 2016 are more comprehensive due to
SPIRIT)
2. Investigator sponsorship versus industry
sponsorship (Hypothesis: industry-sponsored RCT
protocols are more complete and better structured,
thus associated with a larger proportion of adher-
ence to SPIRIT items)
3. Sample size (in 1000 increments) (Hypothesis: larger
trials are better planned and have more
comprehensive protocols, thus associated with a
larger proportion of adherence to SPIRIT items)
4. Single-centre versus multicentre RCTs
(Hypothesis: multi-centre RCTs are better
planned and have more comprehensive protocols,
thus associated with a larger proportion of adher-
ence to SPIRIT items)
5. Lack of methodological support versus support
from a Clinical Research Organization or Clinical
Trial Unit (Hypothesis: protocols mentioning
methodological support are more comprehensive,
thus associated with a larger proportion of
adherence to SPIRIT items)
To directly model the proportion of the SPIRIT
items adhered to per protocol, we will use beta
regression analysis [47]. Using the aggregated propor-
tion as a response does not allow us to capture the
variability within each protocol. Therefore, we will
additionally consider a hierarchical logistic regression
model with two levels: the “SPIRIT item level” and
the “protocol level”. The response is a binary variable
indicating adherence to each SPIRIT item with clus-
tering by protocol. In this approach, we will include
the covariables of interest as fixed effects and the
protocol as a random effect.
For all types of regression analyses, we will report
coefficients or odds ratios (ORs) accompanied by 95%
confidence intervals (CIs). To specifically test our
hypotheses that investigator-sponsored protocols
improved in terms of adherence to SPIRIT between
2012 and 2016 while industry-sponsored protocols did
not (potentially due to a ceiling effect), we will
include a corresponding interaction term (year of
approval * sponsorship) in each of the mentioned
multivariable regression models. We will use the same
approach to test our hypothesis that methodologically
supported protocols (involvement of the Clinical Trial
Unit or Clinical Research Organization) improved less
than RCT protocols without reported methodological
support.
We will provide descriptive statistics as frequencies
and proportions for binary data and mean/median, mini-
mum, maximum, and standard deviation/interquartile
range (IQR) for continuous data. All statistical tests will
be performed at a significance level of 0.05 unless speci-
fied otherwise.
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Statistical analyses for substudies
Subproject 1 (DISCO II study) We will assess how
many RCTs are (i) registered, (ii) published (results in
peer-reviewed journal or trial registry), (iii) registered
and published (peer reviewed journal or trial registry), or
(iv) neither registered nor published. In addition, we will
assess how many registered RCTs were registered pro-
spectively (within 1 month of recruiting first patient) and
how many post hoc, and we will assess the proportion of
unpublished RCTs that were registered (prospectively or
post hoc).
We will descriptively analyse RCTs that were prema-
turely discontinued and list the frequencies and propor-
tions for specific reasons for discontinuation, stratified
by industry and investigator sponsorship as we have pre-
viously done [10] to allow for comparison before and
after publication of the SPIRIT guideline (2000–2003 vs
2012 vs 2016). We will further stratify our analyses by
country of RECs and descriptively compare proportions
to see whether there is any evidence for heterogeneity
across countries. We will use data from the main ASPI
RE study together with DISCO II study data to conduct
two multivariable regression analyses. In the first regres-
sion, “trial discontinuation due to poor recruitment” will
be the dependent variable and the proportion of re-
ported SPIRIT items will be the main independent vari-
able of interest to see whether we can find evidence for
an association between protocol comprehensiveness and
the risk for trial discontinuation due to poor recruit-
ment. Our hypothesis is that less comprehensive proto-
cols are correlated with poorly planned trials leading to
a higher risk of recruitment failure and trial discontinu-
ation. In a second multivariable regression, “trial non-
publication” will be the dependent variable and, again,
the proportion of reported SPIRIT items will be the
main independent variable to explore for an association
between protocol comprehensiveness and non-
publication of trials. Our hypothesis is that less compre-
hensive protocols are correlated with less professional
trial conduct and result in reporting leading to a higher
risk of non-publication.
In an additional study, we will assess if specific RCT
characteristics are different between approved protocols,
information in trial registries, and publications. Specific-
ally, we will check for differences in the following
characteristics:
 Primary outcome
 Planned sample size




 Planned subgroup analyses
 RCT results (published in peer reviewed journals vs
trial registries)
Subproject 2 (Patient-reported outcomes study) De-
scriptive analysis of RCT characteristics and patient-
reported outcome data.
Subproject 3 (Non-regulated interventions study)
Descriptive analysis of ASPIRE data stratified by RCTs
with “regulated interventions” such as drugs, biologics,
or medical devices, and “non-regulated interventions”
such as dietary interventions, surgical procedures,
behavioural and lifestyle interventions or exercise pro-
grammes, and others. We will use the same multivari-
able regression models as described for the ASPIRE
study but include “regulated intervention” (yes vs no) as
an additional independent variable. To test for an effect
modification with year of REC approval (2012 vs 2016),
we will add a corresponding interaction term (year of
approval * regulated intervention) to the regression
model. Our hypothesis is that RCT protocols with regu-
lated interventions are better planned due to the more
stringent regulatory requirements and, therefore, have
more comprehensive protocols associated with a larger
proportion of adherence overall; however, the improve-
ment in adherence of RCT protocols from 2012 to 2016
may be more pronounced in RCT protocols with non-
regulated interventions.
Subproject 4 (Subgroups study) Descriptive analysis of
RCT characteristics with respect to planned subgroup
analyses.
Subproject 5 (Routinely collected data study) Descrip-
tive analysis of RCT characteristics and types and pur-
poses of routinely collected data to support RCTs.
Discussions
The ASPIRE study and the five outlined substudies have
the overall aim to monitor and ultimately inform im-
provements in the planning, conduct, analysis, and
reporting of RCTs. Our findings will inform multiple
aspects of RCT design, protocol completeness, and prac-
tical aspects such as trial registration, premature discon-
tinuation, and non-publication of RCTs observing
potential changes over time. There may be further stud-
ies making use of the collected data, in particular poten-
tial comparisons of RCT information documented in
trial registries with trial protocols and with correspond-
ing publications.
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Strengths and limitations
Strengths of our proposed studies include full access to
protocols and associated documents of all included
RCTs approved by RECs in Switzerland, the UK,
Germany, and Canada in 2012 and 2016. Involved re-
searchers are formally trained methodologists, and we
will use standardized methods of data collection. We will
pre-pilot all data extraction forms with detailed instruc-
tions and carry out calibration exercises to align study
processes. With all Swiss RECs participating in this
international study, the data will be highly representative
of Switzerland and will allow us to explore for differ-
ences between Swiss and other RECs. We specifically
planned to conduct a subgroup analysis to investigate
whether the completeness of Swiss RCT protocols is dif-
ferent from non-Swiss RCT protocols, because a new
federal Law on Research in Humans (Human Research
Act) and its subsidiary ordinances came into effect in
January 2014. Consequently, the roles and operating
procedures of the Swiss RECs and the drug licencing
authority Swissmedic were revised. In this context, new
guidance documents for trial protocols that built on the
SPIRIT recommendations (www.swissethics.ch) were
promoted to Swiss researchers.
Our study has several limitations. First, we are using
a convenience sample of 21 RECs outside of
Switzerland (Freiburg in Germany, Hamilton in
Canada, and 19 RECs of the Bristol regional office). We
cannot say whether they are representative of other
RECs in these or other countries; however, to our
knowledge, they are not in any way particular. Second,
since we will include RCT protocols in the ASPIRE
study that have already been approved by RECs, SPIRIT
items such as “research ethics approval” and “consent
forms provided” will always be fulfilled and will, there-
fore, not contribute to discriminate more complete pro-
tocols from less complete protocols. Third, in our
operationalization of the SPIRIT checklist for data ex-
traction purposes, we did not consider all individual
components of each SPIRIT item but included all major
items and selected components as described in our
methods section. Involved experts felt that not all 270
individual components of SPIRIT items were necessary
for the study and considering all would add unneces-
sary complexity and burden for data extractors. Finally,
our assumption that the adherence to SPIRIT as a
measure for the completeness of reporting of RCT pro-
tocols indeed reflects the “quality of RCT conduct in
general” is based on scientific reasoning and common
sense rather than empirical evidence. To address this
question, we designed the DISCO II substudy to further
investigate the association of protocol adherence to
SPIRIT and premature discontinuation due to poor
recruitment or non-publication of RCTs.
Significance
The impact of poorly planned RCTs is pervasive to the
entire research process, wastes scarce resources, and
may have harmful consequences for all stakeholders in-
cluding patients, decision makers, and the scientific
community, thus affecting society as a whole. To better
understand and ultimately improve the clinical research
process, and RCTs in particular, it is necessary to empir-
ically and systematically investigate the design, methods,
and dissemination of recent RCTs. The present inter-
national study of RCT protocols approved in 2012 or
2016 will provide information on the completeness of
trial protocols and potential changes between 2012 and
2016. Our plan of research will identify reporting defi-
ciencies and associated RCT characteristics and clarify
whether protocol adherence to SPIRIT recommenda-
tions is associated with the proportion of prematurely
discontinued RCTs or the proportion of unpublished
RCTs. Our study will investigate the use of patient-
reported outcomes and HRQoL outcomes in RCTs over
time; compare characteristics of RCTs testing regulated
interventions versus non-regulated interventions; exam-
ine the planning of subgroup analyses in RCTs over
time; and assess the use and specific purposes of rou-
tinely collected data to support RCTs.
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